News in Brief
Health - Feb 26
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
Pharmacology - Feb 26
Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
Pharmacology - Feb 26
Novartis Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Novartis Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Health - Feb 26
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
Administration - Feb 25
Federal bilateral programmes for cooperation in research and innovation with non-European partner countries 2021-2024
Federal bilateral programmes for cooperation in research and innovation with non-European partner countries 2021-2024
wire - news in brief
« BACK
Health - Pharmacology - 26.02.2021
Pharmacology - Health - 26.02.2021
Pharmacology - Health - 26.02.2021
Health - Pharmacology - 26.02.2021
Life Sciences - Health - 25.02.2021
Health - Pharmacology - 25.02.2021
Innovation - Health - 24.02.2021
Health - Sport - 24.02.2021
Health - Environment - 19.02.2021 
Young Researchers in Environmental Epidemiology Share Latest Findings
Swiss TPH and the European Chapter of the International Society of Environmental Epidemiology (ISEE) hosted a virtual symposium for young scientists in the field of environmental epidemiology from 18 to 19 February 2021.
Health - Pharmacology - 17.02.2021
Health - Social Sciences - 17.02.2021
Health - Pharmacology - 16.02.2021
Pharmacology - Health - 16.02.2021
Pharmacology - Health - 12.02.2021
Health - Pharmacology - 10.02.2021 
A very aggressive cancer defeated in three months
A team from the University of Geneva and HUG managed to save a woman whose aggressive cancer left her with only five months to live.
Environment - Health - 10.02.2021 
Six new EPFL - African universities research projects
As part of the EPFL - UM6P 's Excellence in Africa initiative, the EXAF centre has announced the names of the six successful teams which will take part in the Junior Faculty Development programme (JFD).
Health - Pharmacology - 08.02.2021
Pharmacology - Health - 08.02.2021
Health - 08.02.2021 
Improving Access to COVID-19 Screening and Testing in African Countries
A new joint initiative from the Botnar Research Centre for Child Health and the European and Developing Countries Clinical Trials Partnership will support three COVID-19-related projects in lowand mi
Health - 03.02.2021 
Insulin can be stored out of refrigeration in hot settings!
A team from the University of Geneva and MSF has shown that a vial of insulin can be stored for 4 weeks after opening and at up to 37°C,without losing efficacy.
Health - Social Sciences - 03.02.2021
Health - Administration - 03.02.2021
Health - Innovation - 02.02.2021 
Innovative mechanical system makes it easy to turn bedridden patients
A mechanical system developed at EPFL's Instant-Lab halves the number of hospital staff needed to turn coma patients and makes the task less physically demanding.
Health - 01.02.2021 
"Our goal must be low case numbers"
Tanja Stadler, ETH Professor of Computational Evolution, is working at the forefront in the fight against the coronavirus.
Health - Life Sciences - 01.02.2021 
A key regulator for humoral immunity and B lymphoma
The generation of antibodies in B-cells takes place in a dynamic structure that forms during infections, the germinal center (GC).
Pharmacology - Health - 29.01.2021
Health - Economics / Business - 29.01.2021 
Mitigating the Impact of COVID-19 on Neglected Tropical Diseases
The unprecedented progress made in global health over the past 20 years is being threatened by the COVID-19 pandemic.
Health - Pharmacology - 29.01.2021
Pharmacology - Health - 29.01.2021
Health - 28.01.2021 
Wyss Center joins Wellcome Leap global network dedicated to accelerated breakthroughs in human health
Charter group of 21 world-class institutions representing a network of over 150,000 researchers across six continents sign agreement that sets new bar for fast-paced research and development. Geneva, Switzerland: The Wyss Center announced today that it has joined the Leap Health Breakthrough Network , a global group of leading academic and research institutions committed to solving the world's most serious health challenges - such as cancer and infectious diseases - at record speed.
Health - Pharmacology - 28.01.2021
Health - 27.01.2021
Health - Economics / Business - 26.01.2021
Pharmacology - Health - 26.01.2021
Health - Pharmacology - 25.01.2021 
A treatment for every kind of cancer
Researchers from the University of Basel have identified cells in the immune system that are able to attack a wide range of cancer cells.
Health - Pharmacology - 25.01.2021
Environment - Health - 21.01.2021 
Customising legionella control measures
Legionella in drinking water systems can pose a health risk. But the complexity of the stagnation issue means that a much more nuanced approach is required to manage this risk than has previously been supposed. Questioning conventional wisdom is part of the scientist's job. This also applies to legionella in plumbing systems.
Health - Veterinary - 20.01.2021
Psychology - Health - 20.01.2021
Health - Pharmacology - 19.01.2021
Health - Economics / Business - 18.01.2021
Health - Innovation - 15.01.2021
Pharmacology - Health - 14.01.2021
Health - Career - 13.01.2021
Health - Pharmacology - 12.01.2021
Health - 12.01.2021
Pharmacology - Health - 12.01.2021
Health - Pharmacology - 11.01.2021
Life Sciences - Health - 11.01.2021 
4D-Simulator breakthrough in brain surgery
Aneurysm operations in the brain rank among the most delicate procedures in neurosurgery.
Pharmacology - Health - 11.01.2021
Health
Results 1 - 50 of 2160.
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
CHMP has completed a review of available data for investigational antibody cocktail casirivimab and imdevimab (REGN-COV2) to be considered for the treatment of confirmed COVID-19 CHMP scientific op
CHMP has completed a review of available data for investigational antibody cocktail casirivimab and imdevimab (REGN-COV2) to be considered for the treatment of confirmed COVID-19 CHMP scientific op
Novartis Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Cosentyx (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations of PsA in a dedicated trial 1,2 ,3 .
Cosentyx (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations of PsA in a dedicated trial 1,2 ,3 .
Wyss Center joins $36M international collaboration to improve recovery from spinal cord injuries
Geneva, Switzerland - The Wyss Center has joined forces with an international consortium of universities, biomedical startups and nonprofit organizations to develop therapies for spinal cord injury that could improve long-term recovery.
Geneva, Switzerland - The Wyss Center has joined forces with an international consortium of universities, biomedical startups and nonprofit organizations to develop therapies for spinal cord injury that could improve long-term recovery.
Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine
FIREFISH Part 1 data show treatment with Evrysdi at 12 months helped 90% of these infants survive without permanent ventilation and 33% sit without support, a key motor milestone not normally seen in
FIREFISH Part 1 data show treatment with Evrysdi at 12 months helped 90% of these infants survive without permanent ventilation and 33% sit without support, a key motor milestone not normally seen in
SUPSI and IRSOL enter agreement for scientific collaboration in solar research
The University of Applied Sciences and Arts of Southern Switzerland (SUPSI) and the Istituto Ricerche Solari Locarno (IRSOL, affiliated to USI) have signed a collaboration agreement that will consoli
The University of Applied Sciences and Arts of Southern Switzerland (SUPSI) and the Istituto Ricerche Solari Locarno (IRSOL, affiliated to USI) have signed a collaboration agreement that will consoli
Swiss TPH and the European Chapter of the International Society of Environmental Epidemiology (ISEE) hosted a virtual symposium for young scientists in the field of environmental epidemiology from 18 to 19 February 2021.
Novartis Entresto granted expanded indication in chronic heart failure by FDA
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFr
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFr
A team from the University of Geneva and HUG managed to save a woman whose aggressive cancer left her with only five months to live.
As part of the EPFL - UM6P 's Excellence in Africa initiative, the EXAF centre has announced the names of the six successful teams which will take part in the Junior Faculty Development programme (JFD).
Novartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia
Designation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an investigat
Designation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an investigat
A new joint initiative from the Botnar Research Centre for Child Health and the European and Developing Countries Clinical Trials Partnership will support three COVID-19-related projects in lowand mi
A team from the University of Geneva and MSF has shown that a vial of insulin can be stored for 4 weeks after opening and at up to 37°C,without losing efficacy.
A mechanical system developed at EPFL's Instant-Lab halves the number of hospital staff needed to turn coma patients and makes the task less physically demanding.
Tanja Stadler, ETH Professor of Computational Evolution, is working at the forefront in the fight against the coronavirus.
The generation of antibodies in B-cells takes place in a dynamic structure that forms during infections, the germinal center (GC).
The unprecedented progress made in global health over the past 20 years is being threatened by the COVID-19 pandemic.
Novartis receives positive CHMP opinion for Kesimpta * (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS 1 CHMP opinion is base
Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS 1 CHMP opinion is base
Charter group of 21 world-class institutions representing a network of over 150,000 researchers across six continents sign agreement that sets new bar for fast-paced research and development. Geneva, Switzerland: The Wyss Center announced today that it has joined the Leap Health Breakthrough Network , a global group of leading academic and research institutions committed to solving the world's most serious health challenges - such as cancer and infectious diseases - at record speed.
Coronavirus: Federal Council to cover costs of tests for persons without symptoms and modify quarantine rules
At its meeting on 27 January, the Federal Council took a range of decisions to further contain and overcome the coronavirus pandemic.
At its meeting on 27 January, the Federal Council took a range of decisions to further contain and overcome the coronavirus pandemic.
We need to track down hidden infections
Widespread and repeated testing, including of healthy people, is an effective tool in the fight against COVID-19, write Patrick Jenny and Wolf-Dietrich Hardt.
Widespread and repeated testing, including of healthy people, is an effective tool in the fight against COVID-19, write Patrick Jenny and Wolf-Dietrich Hardt.
Researchers from the University of Basel have identified cells in the immune system that are able to attack a wide range of cancer cells.
A new ’double’ antibody that protects against Covid-19 and its variations discovered in Ticino
The Institute for Research in Biomedicine (IRB, affiliated to USI Universitą della Svizzera italiana, has developed a second-generation 'double antibody' that protects from SARS-CoV-2, the virus causing COVID-19, and all its tested variants.
The Institute for Research in Biomedicine (IRB, affiliated to USI Universitą della Svizzera italiana, has developed a second-generation 'double antibody' that protects from SARS-CoV-2, the virus causing COVID-19, and all its tested variants.
Legionella in drinking water systems can pose a health risk. But the complexity of the stagnation issue means that a much more nuanced approach is required to manage this risk than has previously been supposed. Questioning conventional wisdom is part of the scientist's job. This also applies to legionella in plumbing systems.
We need a Grey New Deal
Mental illnesses do not receive the attention they deserve and they are treated as taboo, writes Gerhard Schratt.
Mental illnesses do not receive the attention they deserve and they are treated as taboo, writes Gerhard Schratt.
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1 Currently th
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1 Currently th
Coronavirus: Federal Council extends and tightens measures
Case numbers are stagnating at a very high level and there is a risk that the new more infectious variants of the virus will lead to another rapid rise in cases.
Case numbers are stagnating at a very high level and there is a risk that the new more infectious variants of the virus will lead to another rapid rise in cases.
Second COVID-19 vaccine approved for Switzerland
On 12 January 2021 Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, approved the second COVID-19 vaccination for the Swiss market.
On 12 January 2021 Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, approved the second COVID-19 vaccination for the Swiss market.
Aneurysm operations in the brain rank among the most delicate procedures in neurosurgery.
News in Brief
Health - Feb 26
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
Pharmacology - Feb 26
Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
Pharmacology - Feb 26
Novartis Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Novartis Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Health - Feb 26
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
Administration - Feb 25
Federal bilateral programmes for cooperation in research and innovation with non-European partner countries 2021-2024
Federal bilateral programmes for cooperation in research and innovation with non-European partner countries 2021-2024